Section 32

Portfolio

Investment activity

1 portfolio exit on record.

Q&A

What is Section 32's primary investment focus by sector?

Section 32 primarily focuses its investments within the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name a notable exit for Section 32?

In January 2024, Section 32 saw an exit with the acquisition of C2i Genomics by Veracyte for $95 million.

Which funding stages does Section 32 typically participate in?

Section 32 has participated in B Round funding stages, including both initial and follow-on investments.

What is one of Section 32's active portfolio companies?

Nucleai, a Spatial Biology Software Platform for Precision Medicine, is one of Section 32's active portfolio companies. It raised a $60.5 million Series B round.

When was Section 32 founded?

Section 32 was founded in 2021.

What is the typical investment range for Section 32?

Section 32's investment range is between $14 million and $100 million.